Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs) New York, London 27 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ( Tiziana or the Company ), a biotec

Tiziana Life Sciences Announces

Timetable of Demerger of Accustem

(for holders of Tiziana ADRs)

New York, London 27 October 2020 - Tiziana

Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company

focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it is confirming the

timetable for the Accustem Sciences Limited ("Accustem") demerger (the "Demerger") for holders

of the Company's American Depositary Receipts ("ADRs").

The demerger of Accustem is the spinoff of

Tiziana's StemprintER, a novel biology-based genomic predictor of distant recurrence in breast cancer. In two posters presented

at ASCO, StemPrintER outperformed Oncotype DX in 10-year risk prediction in more than 800 ER+/HER2-postmenopausal breast cancer

patients, including lymph node-negative (N0) and 1 to 3 lymph node-positive (N1-3) patients. The integration of the stem cell biology-based

genomic tool, StemPrintER, with clinicopathological parameters for the prediction of distant recurrence in ER+/HER2-breast cancer

patients demonstrated that the next-generation StemPrintER RiskScore (SPARE) model is approximately 20% superior to the traditional

clinicopathological parameters, as expressed by the CTS, in providing prognostic information in more than 1,800 ER+/HER2-patients

analyzed; and up to 40%-50% more accurate in lymph node-negative (N0) and 1 to 3 lymph node-positive (N1-3) patients.

The timetable for the Demerger and the record date for distribution

of the Accustem ADRs to the holders of Tiziana ADRs is as follows:

* These dates are the same for holders of Tiziana Shares and Tiziana

** From 5:00pm (EDT) on 28 October 2020, the portion of the Tiziana

ADR register regarding the issuance and cancellation of ADRs held by JPMorgan as Depositary Bank for the ADR Program will be closed

until this action is completed. This action will not suspend Nasdaq trading of the Tiziana ADSs. However, for technical reasons,

the ADR Record Date can only be established at a later date.

***Due to complexities of the US securities

laws and the rules of the Nasdaq Capital Market, the ex-entitlement date for holders of the Tiziana ADRs (traded on Nasdaq) is

dependent on the actual delivery date of the new Accustem ADRs (which will each represent 2 Accustem Shares to mirror the position

of the Tiziana ADRs); this is different than the "ex date" of the Tiziana Shares for the purposes of the corporate actions

timetable of the London Stock Exchange plc, but the difference has no economic impact on holders of the ADRs.

The Company plans to file a registration

statement for the new Accustem Shares with the SEC and create a new registered Accustem ADR program. The Accustem ADRs will be

distributed to the holders of Tiziana ADRs as of the Record Date as and when the registration statements become effective. This

is likely to be on or about the date upon which holders of Tiziana Shares receive their new Accustem Shares and it is further likely

to be on or about the date upon which the new Accustem Shares are admitted to trading on the Main Market of the London Stock Exchange

plc (subject to appropriate regulatory review and approvals). The Company will endeavour to ensure dates coincide for these events

in so far as is practicable and will publish additional updates to timelines in due course.

For further enquiries:

United States Investors:

United Kingdom Investors: